We develop
Digital Therapeutics for patients with neurodegenerative diseases
History, Investment, and News
During the past year, Emocog raised funds and
established partnerships with renowned companies worldwide.
Company
2021
-
Emocog, founded (2021.01.19)
-
Certified research facility, established
-
DTA (Digital Therapeutics Alliance) Membership
-
Venture company certification
-
‘Excellence Award’ recognized by Seoul SMEs and Startups
Seed Funding Round
-
Naver-Stonebridge
-
Kakao-Shinhan Bank
-
Naver D2SF
2022
Pre-Series A Funding Round
-
Naver-Stonebridge
-
Kakao-Shinhan Bank
-
SV Investment
-
Green Cross Holdings
-
‘Best Company Award’ recognized by Seoul Startup Hub
-
Emocog Germany branch, established
-
Emocog Germany branch accepted to 5-HT hub by
-
German Ministry of Economic Affairs
Partners
Our Leaders
The founders of Emocog are all medical professors and experts. Our employees are from leading companies around the world, united by a global mindset and a strong passion for what we do.
Leadership
Founder
Jun Young Lee
MD, PhD
Seoul National University College of Medicine, PhD (Psychiatry)
Professor at Seoul National University College of Medicine (Psychiatry)
Korean Elderly Psychiatric Association
Director of Society for Cognitive Intervention
Founder
Yoo Hun Noh
PhD
Chung-Ang University College of Medicine, PhD
Former Professor at Chung-Ang University College of Medicine (Human Anatomy)
Consulting Member at KISTEP
Founder
Jung Hae Youn
PhD
Paris 7, PhD
CEO of Cha Psychological Counseling Center
Professor at Cha University College of Medicine (Psychology)
Chief Operating Officer
Seul Gyu Park
Sciences Po Paris, Master’s
(Business Management)
M&A, Finance & Corporate Strategy
Former Big 4 Management Consulting
Chief Strategy Officer / CEO Europe
Johannes Funk
Heidelberg University, Bachelor’s (Economics)
M&A, Finance & Corporate Strategy
Sciences Po Paris Master’s (Economics/Business Management)
Former M&A and Finance at Siemens, Germany, Portugal & Switzerland
EVP / Chief Medical Officer
June Sik Mune
MD, PhD
Seoul National University College of Medicine, Bachelor's
Soonchunyang University College of Medicine, PhD
Former LG Chem, Head of Clinical Development Center
Chief Business Officer
Brian Lim
Korea University, Bachelor’s
(Business Management)
Merck-Harvard Executive Business School
Former Head of Domestic and International Strategy, Business Development, Marketing, Sales at Global Pharmaceutical Company, Merck (MSD)
Chief Technology Officer
Joonsang Jo
Seoul National University, Bachelor’s
(English Language Education, Computer Science and Engineering)
Former SAP Software Engineer
Solution
Dementia Solutions
Cogthera
Cogthera constantly monitors the conditions of patients' cognitive functions and provides personalized cognitive training to strengthen the neural networks, which increases the 'cognitive reserve' and helps with memory.
The app's contents are derived from the concept of Metamemory training, the subject of our founders' long-year research.
*Cognitive reserve: a concept introduced from the distinction between neuropathological and clinical severity of the brain;
one of the factors that determine the prevention and prognosis of dementia.
*Metamemory training provides specific strategies for memory improvement in patients with early signs of cognitive decline (e.g., MCI) by strengthening the brain structure that is responsible for memory functions(i.e. hippocampus) and the integrated neural networks.
Software as a Medical Device
for enhancing early cognitive decline
1
01
Conversation-based interface using vocal cues,
made for the convenience of patients with early cognitive decline.
02
After accurate assessments of the patient’s cognitive ability, training contents are automatically generated via AI technology, providing personalized training with difficulty adjustments.
03
Frees the patient from restraints of professional presence, location, and time. Accessible anytime and anywhere.
Why Emocog
We create technology
that helps sustain
brain health
About 10% of the senior population suffers from dementia. Yet, many patients begin to encounter issues with memory loss in the stage before dementia, known as Mild Cognitive Impairment (MCI).
In comparison to dementia, 25% of the senior population suffers from MCI.
Emocog currently develops Digital therapeutics,
aiming to enhance the cognitive functions of patients in an early stage of cognitive decline.
Why Emocog
Digital Therapeutics
that can be trusted,
developed by
dementia experts
Managing, i.e., proactively taking care of and training cognitive function is just as important as medicine for dementia patients.
We came up with a digital therapeutics product with the concept of a 'digital coach' supporting patients in managing their cognitive functions, available anytime and anywhere.
Emocog provides reliable and personalized solutions to treat cognitive decline by training the brain using digital technology developed by dementia specialists.
Research
Technology
based on world-class scientific results
The results of 20 years of research have been published in
5 leading SCI-indexed journals on brain disease.
*Science Citation Index (SCI): renowned journals carefully selected
based on a strict criteria among science and technology journals
Cogcare
Cogcare consists of Medi-ballet and MMT.
Medi-ballet is a ballet program for the elderly aiming to improve memory by training the body and memory.
Improve your symptoms and upgrade your quality of life with Medi Ballet.
MMT is a training program based on ‘metamemory’ that enhances the cognitive function of the elderly with the help of cognitive training experts.
Memory and cognitive enhancement program
2
News
Come and make a new history
with Emocog
Hiring All Positions Now
We develop
‘Digital Therapeutics’ for patients with neurodegenerative diseases
Why Emocog
We create technology that helps sustain brain health
About 10% of the senior population suffers from dementia. Yet, many patients begin to encounter issues with memory loss in the stage before dementia, known as Mild Cognitive Impairment (MCI). In comparison to dementia, 25% of the senior population suffers from MCI.
Emocog currently develops Digital therapeutics, aiming to enhance the cognitive functions of patients in an early stage of cognitive decline.
Why Emocog
Digital Therapeutics that can be trusted, developed by dementia experts
Managing, i.e., proactively taking care of and training cognitive function is just as important as medicine for dementia patients.
We came up with a digital therapeutics product with the concept of a ‘digital coach’ supporting patients in managing their cognitive functions, available anytime and anywhere.
Emocog provides reliable and personalized solutions to treat cognitive decline by training the brain using digital technology developed by dementia specialists.
